ALC-0159

Cat. No.:	HY-138300
CAS No.:	1849616-42-7
Molecular Formula:	$(C_2H_4O)nC_{31}H_{63}NO_2$
Target:	Liposome
Pathway:	Metabolic Enzyme/Protease

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (Need ultrasonic)
Ethanol : ≥ 50 mg/mL
* "≥" means soluble, but saturation unknown.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (Infinity mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (Infinity mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (Infinity mM); Clear solution

BIOLOGICAL ACTIVITY

Description

ALC-0159, a polyethylene glycol (PEG) lipid conjugate, could be used as vaccine excipient[1].

In Vitro

ALC-0159, which contributes to nanoparticle stabilization by a steric mechanism through its poly(ethylene glycol) (PEG) moiety[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. S Moein Moghimi, et al. Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines. Mol Ther. 2021 Mar 3;29(3):898-900.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA